Trial Profile
A 6-month, double-blind, randomized, placebo-controlled, parallel group outpatient trial, investigating the efficacy and safety of Org 50081 in adult patients with chronic primary insomnia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Esmirtazapine (Primary)
- Indications Insomnia
- Focus Registrational; Therapeutic Use
- Acronyms AQUAMARINE
- Sponsors Merck Sharp & Dohme; Organon; Schering-Plough
- 21 Jul 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 15 Mar 2012 This trial is recruiting in United Kingdom and France and prematurely ended in Sweden (Parent trial; EudraCT2007-005236-92).
- 15 Mar 2012 Planned number of patients changed from 186 to 440 as reported by EudraCT. (Parent trial; EudraCT2007-005236-92)